Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04268706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

StatusActive, Not Recruiting
PhasePhase 2
Started2021-02-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 5, 2023 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.

Amendment record

Amended 7 times since 2020-02-12; most recent filed 2023-04-04. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2023-04-04
Amendment Study Status v7
2022-04-03
Amendment Recruiting→Active, Not Recruiting Study Identification, Study Status, Study Design, Contacts/Locations v6
2021-03-22
Amendment Study Status v5
2021-03-21
Amendment Study Status, Contacts/Locations v4
2021-02-03
Amendment Not Yet Recruiting→Recruiting Study Identification, Study Status, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v3
2021-01-05
Amendment Study Status, Contacts/Locations v2
2020-11-25
Amendment Study Status, Contacts/Locations v1
2020-02-12
Original filing
Trial Details
NCT Number NCT04268706
Lead Sponsor Tessa Therapeutics
Conditions Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
Enrollment 97 participants
Start Date 2021-02-01
Primary Completion 2025-05 (estimated)
Study Completion 2037-03 (estimated)
Updated on ClinicalTrials.gov 2023-04-05